Search results for "From Annals of Internal Medicine"
SGLT-2s reduced risk for heart failure hospitalization compared to GLP-1s
The retrospective, nonrandomized comparison also found that risk for myocardial infarction or stroke differed by whether type 2 diabetes patients had cardiovascular disease at the time they started a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist.
https://diabetes.acponline.org/archives/2021/10/08/6.htm
8 Oct 2021
Sotagliflozin linked to more days alive, out of hospital in patients with type 2 diabetes recently hospitalized for heart failure
During a median of nine months of follow-up, daily treatment with 200 to 400 mg/d of the experimental drug was associated with about three more days alive and out of the hospital compared to placebo in an industry-funded randomized trial.
https://diabetes.acponline.org/archives/2021/07/09/6.htm
9 Jul 2021
SGLT-2 revisited: Diabetes management in chronic kidney disease
The latest episode of Annals On Call features host Robert M. Centor, MD, MACP, and two guests discussing management of patients who have both diabetes and chronic kidney disease.
https://diabetes.acponline.org/archives/2021/06/11/10.htm
11 Jun 2021
Peripheral neuropathy associated with increased mortality risk, irrespective of diabetes status
Patients with both diabetes and peripheral neuropathy had the highest risk of death during the study's 13-year follow-up, but the next highest rate was in patients with peripheral neuropathy but no diabetes, followed by those with diabetes without peripheral neuropathy.
https://diabetes.acponline.org/archives/2020/12/11/6.htm
11 Dec 2020
Recent KDIGO guideline focused on patients with diabetes and kidney disease
A new summary of the guideline from Kidney Disease: Improving Global Outcomes (KDIGO) highlights important points for clinicians, including recommendations about prescribing of diabetes medications.
https://diabetes.acponline.org/archives/2020/11/13/7.htm
13 Nov 2020
Improvement in polymyalgia rheumatica associated with improved control of diabetes
A three-case series suggests that tighter glycemic control might allow some patients with type 2 diabetes to avoid glucocorticoid treatment for polymyalgia rheumatica.
https://diabetes.acponline.org/archives/2020/10/09/7.htm
9 Oct 2020
MELAS syndrome and MIDD unmasked by metformin use
A case report described a patient found to have mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome and maternally inherited diabetes and deafness (MIDD).
https://diabetes.acponline.org/archives/2020/09/11/7.htm
11 Sep 2020
Synopsis covers ADA update on pharmaceutical management of type 2 diabetes
Experts summarized the latest guidance on medication therapy from the American Diabetes Association (ADA) in a recent article.
https://diabetes.acponline.org/archives/2020/09/11/6.htm
11 Sep 2020
Canagliflozin can lead to statin toxicity, case report finds
A case report describes a patient who had taken rosuvastatin for five years and had new muscle pain and difficulty ambulating two weeks after initiation of canagliflozin.
https://diabetes.acponline.org/archives/2020/08/14/6.htm
14 Aug 2020
Diabetes drug classes associated with similar outcomes in low-risk patients
A systematic review and network meta-analysis found no differences between treatments for drug-naive patients with type 2 diabetes at low cardiovascular risk, leading the authors to conclude that metformin is justified as a first-line therapy.
https://diabetes.acponline.org/archives/2020/07/10/6.htm
10 Jul 2020